Antimetastatic action of the prostacyclin analog iloprost in the mouse.
The antimetastatic activity of the prostacyclin analog Iloprost has been examined in mice bearing Lewis lung carcinoma. An inhibition of lung colony formation is observed when 100 or 200 micrograms/kg Iloprost are administered i.v. 1 h before i.v. injection of tumor cells, which is dependent on the size of tumor inoculum. The effects of 200 micrograms/kg Iloprost persist for 24 h, and are of the same magnitude as those obtained with 10 mg/kg prostacyclin, which last only for 30 min. When treatment with Iloprost is followed by surgical removal of primary tumor, spontaneous metastasis formation is reduced, and the survival time of the treated animals is significantly increased over controls treated with surgery only. The antimetastatic effects of Iloprost appear dissociated from drug's effects on the hemostatic system of the host as indicated by the clot retraction assay, performed after in vivo treatment, using ADP or tumor cells as platelet aggregating agents. Iloprost thus appears to reduce spontaneous metastasis formation and intraoperative tumor cell dissemination, with pharmacological properties more favourable to therapeutic use than those of prostacyclin.
Sava
G
G
Istituto di Farmacologia, Facoltà di Farmacia, Università di Trieste, Italy.
Perissin
L
L
Zorzet
S
S
Piccini
P
P
Giraldi
T
T
D000818:Animals; D000970:Antineoplastic Agents / Q000494:pharmacology*; D002317:Cardiovascular Agents / Q000494:pharmacology*; D011464:Epoprostenol / Q000494:pharmacology*; D005260:Female; D006487:Hemostasis / Q000187:drug effects; D016285:Iloprost; D008175:Lung Neoplasms / Q000556:secondary; D051379:Mice; D008810:Mice, Inbred C57BL; D009362:Neoplasm Metastasis
D000970:Antineoplastic Agents; D002317:Cardiovascular Agents; D011464:Epoprostenol; D016285:Iloprost